<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450488</url>
  </required_header>
  <id_info>
    <org_study_id>AB04011</org_study_id>
    <nct_id>NCT01450488</nct_id>
  </id_info>
  <brief_title>Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS)</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the activity of oral AB1010, administered at two
      dose levels during 3 years to patients with primary or secondary progressive multiple
      sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in MSFC</measure>
    <time_frame>12 months</time_frame>
    <description>average change in multiple sclerosis functional composite (MSFC) score relative to baseline, with clinical response defined as a &gt; 100% improvement (increase) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSFC subcategories</measure>
    <time_frame>12 months</time_frame>
    <description>timed 25-foot walk (T25FW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFSC subcategories</measure>
    <time_frame>12 months</time_frame>
    <description>9-Hole Peg Test (9-HPT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFSC subcategories</measure>
    <time_frame>12 months</time_frame>
    <description>Paced Auditory Addition Test (PASAT-3'')</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>masitinib 3 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>masitinib 6 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib</intervention_name>
    <description>masitinib 3 mg/kg/day</description>
    <arm_group_label>masitinib 3 mg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib</intervention_name>
    <description>masitinib 6 mg/kg/day</description>
    <arm_group_label>masitinib 6 mg/kg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis
             either primary progressive or secondary progressive without relapse within 2 years
             before inclusion.

          2. Patients with EDSS score in the range of 2 to 6.5, inclusive

          3. EDSS progression â‰¥ 1 point within 2 years before inclusion

        Exclusion Criteria:

          1. Disease other than MS responsible for clinical signs and/or MRI lesions

          2. Secondary progressive MS with relapse in the 2 years before inclusion

          3. Treatment with interferon or glatiramer acetate within four weeks prior to treatment
             allocation

          4. Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to
             treatment allocation.

          5. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes
             zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary progressive multiple sclerosis</keyword>
  <keyword>relapse-free secondary progressive multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

